Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B G Feagan

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Alimentary Pharmacology & Therapeutics|February 17, 2006
CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trialB G Feagan, W J Sandborn, G Lichtenstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2000
Predictors of symptom resolution in patients with community-acquired pneumoniaT J Marrie, C Y Lau, S L Wheeler, et al.
Gut|September 14, 2004
CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trialW J Sandborn, B G Feagan, G Radford-Smith, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|December 18, 2001
Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomicsB G Feagan, R Enns, R N Fedorak, et al.
Inflammatory Bowel Diseases|January 4, 2013
An evaluation of utility measurement in Crohn's diseaseJ C Gregor, J W McDonald, N Klar, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2016
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trialB G Feagan, H Patel, J-F Colombel, et al.
The Cochrane Database of Systematic Reviews|April 23, 2005
Cyclosporine for induction of remission in Crohn's diseaseJ W D McDonald, B G Feagan, D Jewell, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2017
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's diseaseN Vande Casteele, B G Feagan, S Vermeire, et al.
Clinical Therapeutics|April 1, 2000
Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacinC S Palmer, C Zhan, A Elixhauser, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 2, 2000
Treatment and outcomes of community-acquired pneumonia at Canadian hospitalsB G Feagan, T J Marrie, C Y Lau, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Alimentary Pharmacology & Therapeutics|February 17, 2006
CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trialB G Feagan, W J Sandborn, G Lichtenstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2000
Predictors of symptom resolution in patients with community-acquired pneumoniaT J Marrie, C Y Lau, S L Wheeler, et al.
Gut|September 14, 2004
CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trialW J Sandborn, B G Feagan, G Radford-Smith, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|December 18, 2001
Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomicsB G Feagan, R Enns, R N Fedorak, et al.
Inflammatory Bowel Diseases|January 4, 2013
An evaluation of utility measurement in Crohn's diseaseJ C Gregor, J W McDonald, N Klar, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2016
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trialB G Feagan, H Patel, J-F Colombel, et al.
The Cochrane Database of Systematic Reviews|April 23, 2005
Cyclosporine for induction of remission in Crohn's diseaseJ W D McDonald, B G Feagan, D Jewell, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2017
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's diseaseN Vande Casteele, B G Feagan, S Vermeire, et al.
Clinical Therapeutics|April 1, 2000
Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacinC S Palmer, C Zhan, A Elixhauser, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 2, 2000
Treatment and outcomes of community-acquired pneumonia at Canadian hospitalsB G Feagan, T J Marrie, C Y Lau, et al.
Pageof 8